Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM3355 in Huntington's Disease Chorea
NCT05475483Phase 2Completed
- Sponsor
- SOM Biotech
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of bevantolol in Huntington disease (HD), sponsored by SOM Biotech. Started Aug 2022; status: completed.
02
Drugs
bevantolol
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT05475483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475483.